Lexeo Therapeutics, Inc.’s Lock-Up Period Set To End on May 1st (NASDAQ:LXEO)

Lexeo Therapeutics’ (NASDAQ:LXEO) lock-up period is set to expire on Wednesday, May 1st. Lexeo Therapeutics had issued 9,090,910 shares in its public offering on November 3rd. The total size of the offering was $100,000,010 based on an initial share price of $11.00. After the end of the company’s lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO opened at $12.45 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.21. The stock’s fifty day moving average price is $14.16. Lexeo Therapeutics has a 52 week low of $9.00 and a 52 week high of $22.33.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Monday, March 11th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.15). Equities research analysts predict that Lexeo Therapeutics will post -3.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Cornell University acquired a new stake in shares of Lexeo Therapeutics in the first quarter valued at $1,980,000. Eventide Asset Management LLC acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at $40,298,000. Omega Fund Management LLC acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at $28,955,000. Finally, Blackstone Inc. acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at $9,342,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.